Open access

Research Article

9 July 2021

Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age

Authors: Eleanor O Caplan, Anisha M Patel https://orcid.org/0000-0003-1902-905X [email protected], Richard W DeClue, Marina Sehman, Daniel Cornett, Tiffany Fair Shaffer, Karina Raimundo, and Brandon T SuehsAuthor Info & Affiliations

Publication: Journal of Comparative Effectiveness Research

Volume 10, Number 15

https://doi.org/10.2217/cer-2021-0109

PDF OtherFormats

Abstract

Aim: Examine real-world characteristics, treatment patterns, and outcomes among treated persons with hemophilia A (PwHA) stratified by age. Patients & methods: This study utilized US claims data from 1 January 2007–31 July 2018 from the Humana Research Database. Unadjusted comparisons were conducted across PwHA (<18, 18–55, 56–89 years) enrolled in commercial or Medicare Advantage Prescription Drug plans. Results: A total of 294 PwHA were identified; 21.1% experienced ≥1 bleeding event, and 41.2 and 53.1% had evidence of arthropathy or related disorders, and pain, respectively. Along with all-cause and hemophilia-related healthcare resource utilization (HCRU), these were highest among PwHA aged 56–89 years. Conclusion: Insights into treatment, outcomes and HCRU may identify opportunities for enhanced disease management, particularly in older PwHA.

Supplementary Material

File (appendices.xlsx)

Download
162.42 KB

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest

1.

Centers for Disease Control and Prevention. Data & statistics on hemophilia (2019). https://www.cdc.gov/ncbddd/hemophilia/data.html

2.

Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9(4), 418–435 (2003).

3.

Darby SC, Kan SW, Spooner RJ et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 110(3), 815–825 (2007).

4.

Plug I, Van Der Bom JG, Peters M et al. Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study. J. Thromb. Haemost. 4(3), 510–516 (2006).

5.

Franchini M, Tagliaferri A, Mannucci PM. The management of hemophilia in elderly patients. Clin. Interv. Aging 2(3), 361–368 (2007).

6.

Angelini D, Konkle BA, Sood SL. Aging among persons with hemophilia: contemporary concerns. Semin. Hematol. 53(1), 35–39 (2016).

7.

Mannucci PM, Iacobelli M. Progress in the contemporary management of hemophilia: the new issue of patient aging. Eur. J. Intern. Med. 43, 16–21 (2017).

•• Discusses how improvements in hemophilia care have led to an aging population of people with hemophilia A, and the common comorbidities in this population that can complicate their management.

8.

Lyons J, Desai V, Xu Y et al. Development and validation of an algorithm for identifying patients with hemophilia A in an administrative claims database. Value Health 21(9), 1098–1103 (2018).

9.

Fryar CD, Gu Q, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2011–2014. Vital Health Stat. 3 39, 1–46 (2016).

10.

Srivastava A, Santagostino E, Dougall A et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 26(Suppl. 6), 1–158 (2020).

• The latest edition of the World Federation of Hemophilia Guidelines for the Management of Hemophilia. The guidelines provide recommendations on therapeutic approaches and principles of care for people with hemophila, including management of comorbidities and medical issues with aging.

11.

Shrestha A, Eldar-Lissai A, Hou N, Lakdawalla DN, Batt K. Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia 23(4), e267–e275 (2017).

•• This US claims-based study (2004–2012) identifies hemophilia A-related healthcare utilization, healthcare costs and prophylaxis or nonprophylaxis treatment among males with hemophilia aged 6–64 years old. It concludes that initiating prophylaxis earlier in life may reduce the healthcare cost burden and long-term complications.

12.

Centers for Medicase & Medicaid Services. Essential Community Providers (ECP) – final 2017 ECP list. https://dbdgateway.cdc.gov/HTCDirSearch.aspx

13.

Centers for Disease Control and Prevention. Hemophilia Treatment Center (HTC) directory. https://dbdgateway.cdc.gov/HTCDirSearch.aspx

14.

Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care 43(11), 1130–1139 (2005).

15.

Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J. Clin. Epidemiol. 53(12), 1258–1267 (2000).

16.

Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med. Care 36(1), 8–27 (1998).

17.

Sloan KL, Sales AE, Liu CF et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med. Care 41(6), 761–774 (2003).

18.

Faurot KR, Jonsson Funk M, Pate V et al. Using claims data to predict dependency in activities of daily living as a proxy for frailty. Pharmacoepidemiol. Drug Saf. 24(1), 59–66 (2015).

19.

Centers for Disease Control and Prevention. Community counts - registry for bleeding disorders surveillance. https://www.hemophilia.org/Bleeding-Disorders/History-of-Bleeding-Disorders

20.

National Hemophilia Foundation. History of bleeding disorders. https://www.hemophilia.org/Bleeding-Disorders/History-of-Bleeding-Disorders

21.

Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood 129(17), 2368–2374 (2017).

•• This publication analyzed patterns of prophylaxis use and its correlation with indicators of arthropathy in people with severe hemophilia A in the US Hemophilia Treatment Center Network and Centers for Disease Control and Prevention registry. It concludes that normal joint function can only be preserved by initiating prophylaxis earlier than 4 years of age.

22.

Office of Disease Prevention and Health Promotion. Community counts hemophilia treatment centers population profile. https://www.healthypeople.gov/2020/data-source/community-counts-hemophilia-treatment-centers-population-profile

23.

Manco-Johnson MJ, Lundin B, Funk S et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J. Thromb. Haemost. 15(11), 2115–2124 (2017).

•• This publication reports the results of a 3-year, open-label, randomized study investigating the impact of prophylaxis versus on-demand therapy for males aged 12–50 years with severe hemophilia A. Those receiving prophylaxis had reduced bleeding, pain and healthcare resource utilization, and improved joint health, activity, satisfaction and health-related quality of life; however, there was no decrease in structural arthropathy progression, suggesting that pre-existing joint arthropathy may be irreversible.

24.

National Organization for Rare Disorders. Hemophilia A. https://rarediseases.org/rare-diseases/hemophilia-a/

25.

Armstrong EP, Malone DC, Krishnan S, Wessler MJ. Costs and utilization of hemophilia A and B patients with and without inhibitors. J. Med. Econ. 17(11), 798–802 (2014).

• This retrospective, observational study utilized US electronic medical records and administrative claims data from 2006–2011 to evaluate health system costs for people with hemophilia A and B with and without inhibitors. The authors found that a higher frequency of hospitalizations and higher costs were associated with inhibitors.

|